Abstract | OBJECTIVE: METHODS: Fifty-six patients in severe infections with SAA who had received granulocyte transfusions combined with G-CSF from 2006 to 2012 in our department were analyzed. A retrospective analysis was undertaken to investigate the survival rates (at 30 days, 90 days and 180 days), the responses to treatment (at 7 days and 30 days, including microbiological, radiographic and clinical responses), the neutrophil count and adverse events after transfusion. RESULTS: All SAA patients with severe infections were treated with granulocyte transfusions combined with G-CSF. Forty-seven patients had received antithymocyte globulin/ antilymphocyte globulin and cyclosporine A as immunosuppressive therapy. The median number of granulocyte components transfused was 18 (range, 3-75). The survival at 30 days, 90 days and 180 days were 50(89%), 39(70%) and 37(66%) respectively. Among 31 patients who had invasive fungal infections, the survival at 30 days, 90 days and 180 days were 27(87%), 18(58%) and 16(52%) respectively. Among the 25 patients who had refractory severe bacterial infections, the survival at 30 days, 90 days and 180 days were 23(92%), 21(84%) and 21(84%) respectively. Survival rate was correlated with hematopoietic recovery. Responses of patients at 7 and 30 days were correlated with survival rate. Common adverse effects of granulocyte transfusion included mild to moderate fever, chills, allergy and dyspnea. CONCLUSION: Granulocyte transfusions combined with G-CSF could be an adjunctive therapy for treating severe infections of patients with SAA.
|
Authors | Huaquan Wang, Yuhong Wu, Rong Fu, Wen Qu, Erbao Ruan, Guojin Wang, Hong Liu, Jia Song, Limin Xing, Jing Guan, Lijuan Li, Chunyan Liu, Zonghong Shao |
Journal | PloS one
(PLoS One)
Vol. 9
Issue 2
Pg. e88148
( 2014)
ISSN: 1932-6203 [Electronic] United States |
PMID | 24505406
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Antilymphocyte Serum
- Immunosuppressive Agents
- Granulocyte Colony-Stimulating Factor
- Cyclosporine
|
Topics |
- Adolescent
- Adult
- Aged
- Anemia, Aplastic
(complications)
- Antilymphocyte Serum
(therapeutic use)
- Bacterial Infections
(complications, therapy)
- Child
- Cyclosporine
(therapeutic use)
- Female
- Granulocyte Colony-Stimulating Factor
(therapeutic use)
- Granulocytes
(cytology, metabolism)
- Humans
- Immunosuppressive Agents
(therapeutic use)
- Leukocyte Transfusion
(methods)
- Male
- Middle Aged
- Mycoses
(complications, therapy)
- Retrospective Studies
- Survival Rate
- Young Adult
|